Exact Sciences (EXAS) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
2.8B
Gross Profit
1.9B
69.55%
Operating Income
-179.1M
-6.49%
Net Income
-1.0B
-37.29%
EPS (Diluted)
-$5.59
Balance Sheet Metrics
Total Assets
5.9B
Total Liabilities
3.5B
Shareholders Equity
2.4B
Debt to Equity
1.47
Cash Flow Metrics
Operating Cash Flow
-694.9M
Free Cash Flow
74.5M
Revenue & Profitability Trend
Exact Sciences Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 2.8B | 2.5B | 2.1B | 1.8B | 1.5B |
| Cost of Goods Sold | 840.2M | 654.2M | 574.4M | 458.8M | 354.3M |
| Gross Profit | 1.9B | 1.8B | 1.5B | 1.3B | 1.1B |
| Operating Expenses | 2.1B | 2.0B | 2.0B | 2.0B | 1.6B |
| Operating Income | -179.1M | -214.3M | -577.5M | -835.5M | -558.0M |
| Pre-tax Income | -1.0B | -201.7M | -632.6M | -842.5M | -829.1M |
| Income Tax | -7.3M | 2.4M | -9.1M | -246.9M | -5.5M |
| Net Income | -1.0B | -204.1M | -623.5M | -595.6M | -823.6M |
| EPS (Diluted) | -$5.59 | -$1.13 | -$3.54 | -$3.48 | -$5.61 |
Income Statement Trend
Exact Sciences Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 1.6B | 1.2B | 982.3M | 1.4B | 2.2B |
| Non-Current Assets | 4.4B | 5.3B | 5.2B | 5.3B | 2.7B |
| Total Assets | 5.9B | 6.5B | 6.2B | 6.7B | 4.9B |
| Liabilities | |||||
| Current Liabilities | 732.2M | 514.7M | 412.7M | 517.1M | 633.1M |
| Non-Current Liabilities | 2.8B | 2.8B | 2.8B | 2.8B | 2.1B |
| Total Liabilities | 3.5B | 3.3B | 3.2B | 3.3B | 2.7B |
| Equity | |||||
| Total Shareholders Equity | 2.4B | 3.1B | 3.0B | 3.4B | 2.2B |
Balance Sheet Composition
Exact Sciences Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -1.0B | -204.1M | -623.5M | -595.6M | -823.6M |
| Operating Cash Flow | -694.9M | 87.2M | -223.8M | -268.9M | -182.0M |
| Investing Activities | |||||
| Capital Expenditures | -136.0M | -124.2M | -214.5M | -135.8M | -65.1M |
| Investing Cash Flow | -442.2M | 49.7M | 74.1M | -1.1B | -702.0M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 199.0M | 128.2M | 44.5M | -29.0M | 1.8B |
| Free Cash Flow | 74.5M | 31.9M | -438.0M | -238.0M | 71.4M |
Cash Flow Trend
Exact Sciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-9.40
Forward P/E
-155.94
Price to Book
4.17
Price to Sales
3.54
PEG Ratio
-155.94
Profitability Ratios
Profit Margin
-36.06%
Operating Margin
-11.53%
Return on Equity
-36.89%
Return on Assets
-1.83%
Financial Health
Current Ratio
2.73
Debt to Equity
105.93
Beta
0.98
Per Share Data
EPS (TTM)
-$5.53
Book Value per Share
$12.71
Revenue per Share
$15.26
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| exas | 10.0B | -9.40 | 4.17 | -36.89% | -36.06% | 105.93 |
| Thermo Fisher | 152.5B | 23.69 | 3.09 | 13.70% | 15.19% | 69.23 |
| Danaher | 140.5B | 37.98 | 2.76 | 7.22% | 15.81% | 34.56 |
| Idexx Laboratories | 42.1B | 48.33 | 29.21 | 59.33% | 22.76% | 73.16 |
| Agilent Technologies | 33.0B | 28.60 | 5.37 | 18.88% | 17.59% | 60.04 |
| Iqvia Holdings | 27.4B | 21.64 | 4.61 | 21.64% | 8.61% | 242.91 |
Financial data is updated regularly. All figures are in the company's reporting currency.